Molecular targeted agents combined with chemo-radiation in the treatment of locally advanced cervix cancer.

Details

Ressource 1Download: Herrera FG Rev Rec Cl Trials 2008.pdf (378.13 [Ko])
State: Public
Version: author
License: Not specified
Serval ID
serval:BIB_3152C51D1022
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Molecular targeted agents combined with chemo-radiation in the treatment of locally advanced cervix cancer.
Journal
Reviews on recent clinical trials
Author(s)
Herrera F.G., Vidal L., Oza A., Milosevic M., Fyles A.
ISSN
1574-8871 (Print)
ISSN-L
1574-8871
Publication state
Published
Issued date
05/2008
Peer-reviewed
Oui
Volume
3
Number
2
Pages
111-120
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Despite improvements in survival after the introduction of chemo-radiotherapy (CRT) in the treatment of patients with cervical cancer, loco-regional control of this disease continues to be a major problem. The present article reviews current and emerging therapeutic strategies combining CRT with novel molecular agents that specifically target the abnormal tumor microenvironment, with the aim of improving local control and survival in patients with locally advanced cervix cancer. The evidence supporting the biological rational to combine novel non-cytotoxic agents with CRT is strong, and drugs targeting different molecular pathways are currently under clinical development (EGFR inhibitors, COX-2 inhibitors, hypoxia targeted agents, etc). Early pre-clinical and clinical strategies also favor the use of vascular-targeted agents with the aim to normalize the abnormal tumor vasculature, increase tumor oxygenation, and reduce interstitial fluid pressure (IFP). The integration of these novel targeted therapies with CRT in clinical trials is discussed, as well as new and promising biomarkers to test drug activity.
Keywords
Antineoplastic Agents/therapeutic use, Cyclooxygenase 2 Inhibitors/therapeutic use, Female, Humans, Immunologic Factors/therapeutic use, Radiation-Sensitizing Agents/therapeutic use, Radiotherapy, Adjuvant, Uterine Cervical Neoplasms/drug therapy, Uterine Cervical Neoplasms/pathology, Uterine Cervical Neoplasms/radiotherapy
Pubmed
Create date
08/04/2020 8:35
Last modification date
28/03/2023 6:09
Usage data